Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Biochim Biophys Acta. 2017 Mar 27;1862(6):636–645. doi: 10.1016/j.bbalip.2017.03.010

Figure 5. Contribution of endothelial 12/15-LO to high glucose (HG)-induced ICAM-1 expression in HRECs.

Figure 5

A) Expression of 12-LO and 15-LO in HRECs and human monocyte-like U937 cells. B) Inhibition of HG-induced ICAM-1 expression, as assessed by Western blot analysis, in HRECs pre-treated with the broad 12/15-LO pharmacological inhibitor, baicalein (10 μM). Cells were pretreated with baicalein for 30 min, and then incubated with (HG; D-Glucose, 30 mM) or normo-osmotic control (LG, 5mM D-glucose+25 mM L-glucose) for 5-days. C&D) Inhibition of HG-induced ICAM-1 expression, as assessed by Western blot analysis, in HRECs transfected with 15-LO siRNA. Cells were transfected with siRNA or mock siRNA for 24 hours and then treated with (HG; D-Glucose, 30 mM) or normo-osmotic control (LG, 5mM D-glucose+25 mM L-glucose) for 5-days. C) Measurement of 15-LO expression relative to actin by Western blot after transfection with 15-LO siRNA. D) Relative ICAM-1 expression in HRECs incubated with HG or LG in the presence or absence of 15-LO siRNA normalized to that of LG and mocked siRNA-treated cells, which was arbitrarily set at 1, n=4–5. E) HRECs were incubated in (HG; D-Glucose, 30 mM) or normo-osmotic control (LG, 5mM D-glucose+25 mM L-glucose) for 5-days in presence of baicalein (10 μM) or its vehicle (DMSO), then subjected to leukocyte adhesion using CD14+ monocytes. The data presented are the fold changes in Myeloperoxidase (MPO) activity (an indicator for leukocyte adhesion) ± SD relative to the corresponding control LG-treated HRECs, n =4 in each group.